Roivant Sciences Ltd.
brepocitinib
lichen planopilaris
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for brepocitinib in lichen planopilaris are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Topline data from Phase 3 studies in non-infectious uveitis (NIU) are expected in the second half of calendar year 2026.”